Munich-DE
Munich-DE-MOBILE

Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)

European Society of Cardiology (ESC) 2026

Congress Details

calanderAugust 28 - 31, 2026

locationMunich, Germany

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

Filters

 

Therapeutic Areas

28 August, 2026

Transthyretin Amyloidosis (ATTR)

Amylo'ExTTRa: Exploring extra-cardiac manifestations in patients with ATTR-CM using a French National Health Data System
icon Presentation Type
Oral Presentation
time icon Time
13:27 - 13:39 CEST
location icon Location
Science Box 3 (Research Gateway Hall A1)
icon Title
Amylo'ExTTRa: Exploring extra-cardiac manifestations in patients with ATTR-CM using a French National Health Data System
mic Presenter

Thibaud Damy

Hôpitaux Universitaires Henri-Mondor
Paris, France

30 August, 2026

Transthyretin Amyloidosis (ATTR)

Vutrisiran is associated with preservation of intrinsic capacity and healthy ageing in patients with transthyretin amyloidosis with cardiomyopathy: Post hoc analysis of HELIOS-B
icon Presentation Type
Oral Presentation
time icon Time
08:15 - 08:25 CEST
location icon Location
Science Box 3 (Research Gateway Hall A1)
icon Title
Vutrisiran is associated with preservation of intrinsic capacity and healthy ageing in patients with transthyretin amyloidosis with cardiomyopathy: Post hoc analysis of HELIOS-B
mic Presenter

Olivier Lairez

Toulouse University Hospital
Tolouse, France

 

Cardiovascular (CV)

Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial
icon Presentation Type
Oral Presentation
time icon Time
08:15 - 08:25 CEST
location icon Location
Science Box 4 (Research Gateway Hall A1)
icon Title
Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial
mic Presenter

Neha Pagidipati

Duke Clinical Research Institute
Durham, NC, USA

Transthyretin Amyloidosis (ATTR)

Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: post hoc safety analysis from HELIOS-B
icon Presentation Type
Moderated Poster
time icon Time
09:15 - 10:00 CEST
location icon Location
Station 5 (Research Gateway Hall A1)
icon Title
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: post hoc safety analysis from HELIOS-B
mic Presenter

Stéphanie Schwarting

Ludwig Maximillian University of Munich
Munich, Germany

 

Transthyretin Amyloidosis (ATTR)

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights from HELIOS-B
icon Presentation Type
Oral Presentation
time icon Time
14:15 - 14:30 CEST
location icon Location
Achgabat (Hall A3)
icon Title
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights from HELIOS-B
mic Presenter

Yasuhiro Hamatani

Brigham and Women's Hospital
Boston, MA, USA

31 August, 2026

Transthyretin Amyloidosis (ATTR)

Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran Phase 3 studies
icon Presentation Type
Oral Presentation
time icon Time
10:00 - 10:10 CEST
location icon Location
Science Box 4 (Research Gateway Hall A1)
icon Title
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran Phase 3 studies
mic Presenter

Amira Zaroui

Assistance Publique-Hôpitaux de Paris
Paris, France

Related Materials

acc-usa-mobile

Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2025

March 29-31, 2025 USA

View Details

Transthyretin Amyloidosis (ATTR)

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study

Orphanet Journal of Rare Diseases

Author(s)

Yann Péréon, David Adams, Jean-Philippe Camdessanché, et al

March 2025

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis with Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Farooq H. Sheikh, Gilbert Habib, W. H. Wilson Tang, et al

March 2025

Transthyretin Amyloidosis (ATTR)

Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, Ronald M. Witteles, Pablo Garcia-Pavia, et al

March 2025

sfnp-2025-mobile

Transthyretin Amyloidosis (ATTR)

Société Francophone du Nerf Périphérique (SFNP) 2025

January 31 - February 1, 2025 France

View Details

Transthyretin Amyloidosis (ATTR)

Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial

Journal of the American College of Cardiology

Author(s)

Marianna Fontana, Mathew S. Maurer, Julian D. Gillmore, et al

January 2025